Retatrutide vs. Tirzepatide vs. Semaglutide: Triple, Dual, and Single Incretin Receptor Agonism

Incretin peptides are, at this point, the most studied class of molecules in metabolic research. Semaglutide, tirzepatide, and retatrutide are cited together so often that the differences between them end up being treated as details. They are not details. The three molecules activate one receptor, two receptors, and three receptors respectively, and this difference in architecture changes everything that matters in a laboratory: the mechanism, the appropriate experimental model, how results are interpreted, and even how the vial is handled.

This article places the three peptides side by side, with data from the published literature, and explains why retatrutide, the triple agonist, is the molecule generating the greatest interest in current research programs.

1. What incretin peptides are

Incretins are intestinal hormones released after a meal. The two main incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). They bind to their own receptors, GLP-1R and GIPR, and amplify glucose-dependent insulin secretion. Native GLP-1 has a half-life of approximately two minutes, which makes it unusable as a research tool without structural modification.

This is the starting point for three generations of synthetic peptides:

• Generation 1: single-receptor agonists (GLP-1R). Semaglutide is the reference representative.
• Generation 2: dual GIPR/GLP-1R co-agonists. Tirzepatide is the first in class.
• Generation 3: triple GIPR/GLP-1R/GCGR agonists, where GCGR is the glucagon receptor. Retatrutide is the reference molecule.

Each generation added a signalling pathway rather than replacing the previous one.

2. Semaglutide: the single GLP-1R agonist

Semaglutide is a GLP-1 analog with 94% homology to the human hormone. Three structural modifications give it its stability: substitution of the amino acid at position 8 (Aib instead of alanine), which blocks enzymatic degradation by DPP-4; a C18 fatty acid chain attached to the lysine at position 26, which binds the molecule to albumin; and substitution of the lysine at position 34 with arginine.

The result is a peptide with a half-life of approximately 160 hours, active exclusively on the GLP-1 receptor. In research, semaglutide is the control molecule when studying the isolated contribution of the GLP-1 pathway: the effect on insulin secretion, gastric emptying, and hypothalamic appetite circuits.

The STEP 1 trial (Wilding et al., NEJM 2021) remains the published reference for the class of single agonists.

3. Tirzepatide: the dual GIPR/GLP-1R co-agonist

Tirzepatide is a synthetic 39-amino-acid peptide built on the native GIP backbone, with modifications that allow it to also activate the GLP-1 receptor. It carries a C20 fatty acid chain attached via a spacer, giving it a half-life of approximately 5 days.

An important technical detail: tirzepatide is an imbalanced agonist. Its affinity for GIPR is comparable to that of native GIP, while its affinity for GLP-1R is approximately five times lower than that of native GLP-1. This asymmetry is part of the design, not a flaw, and it is one of the reasons tirzepatide is used in the laboratory as a model for studying the contribution of the GIP pathway.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) is the published reference for dual co-agonism.

4. Retatrutide: the triple GIPR/GLP-1R/GCGR agonist

Retatrutide (development code LY3437943) is a 39-amino-acid peptide, also built on a GIP backbone, but with modifications that give it activity on three receptors: GIPR, GLP-1R, and the glucagon receptor (GCGR). The C20 fatty acid chain attached to the lysine at position 17 extends its half-life to approximately 6 days.

The activity profile published by Coskun et al. (Cell Metabolism, 2022) describes retatrutide as an agonist with higher affinity for GIPR than for GLP-1R and GCGR, with partial activity on GLP-1R and GCGR. This is the molecule's signature: not three equal activations, but a distribution engineered across the three pathways.

Why does glucagon matter? In preclinical research, GCGR activation has been associated with increased energy expenditure, hepatic lipid oxidation, and effects on hepatic metabolism — mechanisms distinct from those of GLP-1 and GIP, which act predominantly on insulin secretion and appetite. Combining the three pathways in a single molecule was first validated in murine models (Knerr et al., Mol Metab 2022), then in the phase 2 trials published in NEJM and the Lancet in 2023 (Jastreboff et al.; Rosenstock et al.).

5. Comparison table: retatrutide vs. tirzepatide vs. semaglutide

6. What the mechanism differences mean for a research protocol

The choice of molecule depends on the experimental question, not on "which one is newer."

• When studying the GLP-1 pathway exclusively, semaglutide is the clean tool. Any observed effect can be attributed to a single receptor.
• When studying the contribution of GIP on top of GLP-1, tirzepatide provides the dual model, and comparison with semaglutide isolates the GIP effect.
• When studying the role of glucagon in energy and hepatic metabolism, retatrutide is the only molecule in this class that includes GCGR. Comparing retatrutide with tirzepatide isolates the contribution of the glucagon pathway.

For this reason, retatrutide is the most requested of the three in research programs investigating energy expenditure, hepatic steatosis in animal models, and the interaction between incretin and glucagon pathways. It is the molecule with the most open questions still remaining, and therefore the greatest potential for new findings.

7. Published data: what the phase 2 trials show

The phase 2 trial published in NEJM (Jastreboff et al., 2023) evaluated retatrutide in 338 participants, over 48 weeks, at doses between 1 mg and 12 mg. The Lancet trial (Rosenstock et al., 2023) evaluated the molecule in 281 participants with type 2 diabetes, over 36 weeks, with dulaglutide as the active comparator arm. Both trials report a clear dose-response relationship and an adverse event profile dominated by gastrointestinal effects, consistent with the class.

These trials are mentioned for scientific context. PEPTIQUE does not supply retatrutide for human use, and clinical data do not carry over to the research product.

8. Available quantities and experimental models

PEPTIQUE offers lyophilized retatrutide in 3 ml vials, in four quantities: 5 mg, 10 mg, 15 mg, and 30 mg. The quantity is chosen based on the number of samples and the final concentration required after reconstitution:

• 5 mg: pilot studies, receptor-binding assays, analytical method validation.
• 10 mg and 15 mg: standard experimental series, with multiple working concentrations from the same batch.
• 30 mg: extended programs, where batch uniformity across samples is critical.

All quantities come from batches with ≥99% purity, with a certificate of analysis available on request.

9. Reconstitution and storage

Lyophilized retatrutide is stored at 2–8°C, protected from direct light, in its original packaging. For reconstitution, bacteriostatic water (0.9% benzyl alcohol) is used, added slowly along the wall of the vial, without vigorous agitation. The solution is homogenized by gentle swirling until fully dissolved.

A few practical rules:

• Do not freeze the reconstituted solution.
• Label the vial with the reconstitution date and the resulting concentration.
• The solution is stored refrigerated and used within the timeframe set by the laboratory's protocol.
• Peptides with a fatty acid chain, like all three discussed here, are sensitive to mechanical agitation. Avoid the vortex.

A complete reconstitution guide, comparing bacteriostatic water, acetic acid, and matrix water, is available separately on the PEPTIQUE blog.

10. Conclusion

Semaglutide, tirzepatide, and retatrutide are not three versions of the same molecule. They are three answers to three different questions: what GLP-1 does alone, what GIP adds, and what glucagon adds. Retatrutide is the only one that answers the third question, which makes it, at this point, the most interesting peptide in metabolic research.

For laboratories, PEPTIQUE offers retatrutide with ≥99% purity, in four quantities, with batch traceability and certificate of analysis on request. Research use only.